Markets:

Overview

News

Currencies

International

Treasuries

Csl Ltd ADR (OP:CSLLY)

57.67 -0.32 (-0.55%)

Streaming Delayed Price Updated: 1:22 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Csl Ltd ADR

< Previous 1 2 Next >

Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗

March 20, 2023

Via Benzinga

Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand

February 28, 2023

From Amarin Corporation plc

Via GlobeNewswire

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗

February 21, 2023

Via Benzinga

Why CSL Ltd Stock Could Be Worth a Look

December 03, 2022

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

Via MarketBeat

Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines ↗

November 02, 2022

Via Benzinga

CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks ↗

August 17, 2022

Via Benzinga

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗

November 23, 2022

Via Benzinga

Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today? ↗

November 02, 2022

The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology.

Via InvestorPlace

Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder ↗

August 22, 2022

Via Benzinga

Finalization of Vifor Pharma acquisition

August 02, 2022

From Vifor Pharma AG

Via Business Wire

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗

May 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021 ↗

December 14, 2021

Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.